Login to Your Account



FINANCINGS NEWS
Cellular immunotherapy firm Bellicum Pharmaceuticals Inc. landed $55 million in an oversubscribed series C less than eight months after closing its $34.4 million B round, raising the company's total haul to $107 million since launching in 2004.
DEEP BREATH: INHALED LEVODOPA
With its inhaled levodopa product for Parkinson's disease (PD) gearing up for a phase III trial and $55 million just gained in a series C financing, Civitas Therapeutics Inc. filed to raise up to $86.2 million in an initial public offering (IPO).
A SWING-FOR-THE-FENCE STRATEGY
Riding high on a string of successful exits, Arch Venture Partners said Wednesday it closed its eighth fund with more than $400 million in subscriptions, exceeding its $250 million target by more than $150 million.
More FINANCINGS Headlines

Cast Your Vote

Has biotech’s bubble burst?: